ReviewFrontiers in medicine2021

A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab.

Feras M Ghazawi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.